- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07277413
Badanie IDE892 jako monoterapii i terapii skojarzonej w zaawansowanych nowotworach litych z delecją MTAP
Wieloośrodkowe badanie oceniające bezpieczeństwo, skuteczność i farmakokinetykę preparatu IDE892 jako monoterapii i terapii skojarzonej u uczestników z zaawansowanymi guzami litymi z delecją MTAP
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The purpose of this study is to evaluate safety, efficacy, and PK of IDE892 as monotherapy and combination therapy in adult participants with MTAP-deleted tumors who have progressed after standard therapy and represent a high unmet need. In the current stage, the combination will be focused on IDE892 with IDE397, an oral inhibitor of methionine adenosyltransferase 2A (MAT2A), to fully exploit the vulnerabilities associated with methylthioadenosine (MTA) accumulation in MTAP-deleted tumors while maintaining a substantial therapeutic index. The mechanistic rationale for this study is discussed in the following sections.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: IDEAYA Clinical Trials
- Numer telefonu: +1 855 433 2246
- E-mail: IDEAYAClinicalTrials@ideayabio.com
Lokalizacje studiów
-
-
Arizona
-
Goodyear, Arizona, Stany Zjednoczone, 85338
- Rekrutacyjny
- City of Hope Cancer Center-Phoenix
-
Kontakt:
- Amit Kulkarni, MD
- Numer telefonu: 612-624-9604
- E-mail: amkulkarni@coh.org
-
Phoenix, Arizona, Stany Zjednoczone, 85054
- Rekrutacyjny
- Mayo Clinic Arizona
-
Kontakt:
- Mitesh J. Borad, M.D.
- Numer telefonu: 855-776-0015
-
-
California
-
Duarte, California, Stany Zjednoczone, 91010
- Rekrutacyjny
- City of Hope Cancer Center-Duarte
-
Kontakt:
- Abhishek Tripathi, M.D.
- Numer telefonu: 626-218-9200
- E-mail: atripathi@coh.org
-
Santa Rosa, California, Stany Zjednoczone, 95403
- Rekrutacyjny
- Providence Medical Foundation
-
Kontakt:
- Ian Anderson, MD
- Numer telefonu: 707-521-3830
- E-mail: ian.anderson@providence.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20016
- Rekrutacyjny
- Johns Hopkins Sibley Memorial Hospital
-
Kontakt:
- Solmaz Sahebjam, MD
- Numer telefonu: 202-669-6500
- E-mail: ssahebj1@jh.edu
-
Kontakt:
- Mahlet Atnafu
- Numer telefonu: 202-669-6500
- E-mail: SibleyOncResReferral@live.johnshopkins.edu
-
-
Florida
-
Coral Springs, Florida, Stany Zjednoczone, 33065
- Rekrutacyjny
- BRCR Global-Coral Springs
-
Kontakt:
- Alina Quintana
- Numer telefonu: 561-447-0614
- E-mail: alinaq@brcrglobal.com
-
Jacksonville, Florida, Stany Zjednoczone, 32224
- Rekrutacyjny
- Mayo Clinic Florida
-
Kontakt:
- Conor D. O'Donnell, M.B., B.Ch., B.A.O.
- Numer telefonu: 855-776-0015
-
Orlando, Florida, Stany Zjednoczone, 32827
- Rekrutacyjny
- Sarah Cannon Research Institute at Florida Cancer Specialists
-
Kontakt:
- Elizabeth Gilmore
- Numer telefonu: 904-380-2410
- E-mail: Elizabeth.Griffith@Scri.com
-
Tampa, Florida, Stany Zjednoczone, 33612
- Rekrutacyjny
- Moffitt Cancer Center
-
Kontakt:
- Mauricio Ribeiro, MD
- Numer telefonu: 813-745-3242
- E-mail: mauricio.ribeiro@moffitt.org
-
Kontakt:
- Anisa Gonzalez
- Numer telefonu: 813-745-3874
- E-mail: anisa.gonzalez@moffitt.org
-
-
Illinois
-
Zion, Illinois, Stany Zjednoczone, 60099
- Rekrutacyjny
- City of Hope Cancer Center-Chicago
-
Kontakt:
- Evan Pisick, M.D.
- Numer telefonu: 415-353-9674
- E-mail: episick@coh.org
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Rekrutacyjny
- Mayo Clinic Rochester
-
Kontakt:
- Kaushal Parikh, M.B.B.S.
- Numer telefonu: 855-776-0015
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68130
- Rekrutacyjny
- Nebraska Cancer Specialists
-
Kontakt:
- Lindsey Becker, Primary Study Coordinator
- Numer telefonu: 402-691-5255
- E-mail: lbecker@nebraskacancer.com
-
-
New Jersey
-
East Brunswick, New Jersey, Stany Zjednoczone, 08816
- Rekrutacyjny
- START Astera, LLC
-
Kontakt:
- Hope Team Distribution List
- E-mail: hopeteam@startresearch.com
-
-
New York
-
New York, New York, Stany Zjednoczone, 10032
- Rekrutacyjny
- Columbia University Irving Medical Center
-
Kontakt:
- Nurse Navigation Team: Contact for All Patient Referrals
- Numer telefonu: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
- Rekrutacyjny
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
-
Kontakt:
- E-mail: askphase1@jefferson.edu
-
Kontakt:
- askphase1@jefferson.edu
- Numer telefonu: 215-586-0199
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- Rekrutacyjny
- Sarah Cannon Research Institute
-
Kontakt:
- Alydia Miller
- Numer telefonu: 615-927-2212
- E-mail: alydia.miller@scri.com
-
Kontakt:
- Sarah Cannon Institute
- Numer telefonu: 844-482-4812
- E-mail: asksarah@sarahcannon.com
-
-
Texas
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Rekrutacyjny
- START Dallas Fort Worth
-
Kontakt:
- Kasie Newton
- Numer telefonu: 682-350-3010
- E-mail: kasie.newton@startresearch.com
-
Houston, Texas, Stany Zjednoczone, 77030
- Rekrutacyjny
- MD Anderson
-
Kontakt:
- Jordi Rodon Ahnert, MD, PhD
- Numer telefonu: 713-563-1930
- E-mail: JRodon@mdanderson.org
-
Houston, Texas, Stany Zjednoczone, 77054
- Rekrutacyjny
- NEXT Oncology Houston
-
Kontakt:
- Emma Morales
- Numer telefonu: 832-384-7912
- E-mail: emorales@nextoncology.com
-
Irving, Texas, Stany Zjednoczone, 75039
- Rekrutacyjny
- NEXT Oncology Dallas
-
Kontakt:
- Mofopefoluwa Akinwale
- Numer telefonu: 972-893-8800
- E-mail: fakinwale@nextoncology.com
-
-
Utah
-
West Valley City, Utah, Stany Zjednoczone, 84119
- Rekrutacyjny
- START Mountain Region, LLC
-
Kontakt:
- Marie Asay, Director, Nursing
- Numer telefonu: 801-907-4770
- E-mail: marie.asay@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Stany Zjednoczone, 22031
- Rekrutacyjny
- NEXT Oncology Virginia
-
Kontakt:
- Maybelle De La Rosa
- Numer telefonu: 703-783-4518
- E-mail: mdelarosa@nextoncology.com
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98104
- Rekrutacyjny
- Swedish Cancer Institute
-
Kontakt:
- Siddhartha Devarakonda, MD
- Numer telefonu: 206-386-2424
- E-mail: siddhartha.devarakonda@swedish.org
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.
- Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose escalation: mesothelioma [pleural or peritoneal], gastroesophageal cancers [squamous and adenocarcinoma of esophagus, gastric adenocarcinoma, gastroesophageal junction cancers], pancreatic adenocarcinoma and biliary tract carcinomas (intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer), NSCLC [adenocarcinoma, squamous cell carcinoma, and adeno-squamous] or UC [including mixed urothelial-squamous histology]; for dose expansion: NSCLC that has progressed on at least one prior line of treatment and for which additional effective standard therapy is not available or for which the participant is not a candidate due to intolerance).
- Are willing and able to provide blood/tumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central confirmation of MTAP loss.
- Must be willing and able to provide the blood/serum/plasma samples
- Have evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)
- Have at least 1 measurable lesion according to RECIST version 1.1
- Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
- Have life expectancy > 3 months
- Have adequate bone marrow and organ function
- Able to swallow and retain orally administered study drug/IMP.
- Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
- Male and female: willing to use contraception
Exclusion Criteria:
- Known symptomatic brain metastases requiring supraphysiologic doses of systemic corticosteroids
- Have a known primary central nervous system (CNS) malignancy
- Have had other malignancies within 2 years prior to the first dose, with some exceptions
- Impaired cardiac function or clinically significant cardiac diseases
- Have presence of uncontrolled pleural, peritoneal, or pericardial effusion within 2 weeks before the first study dose, requiring recurrent drainage procedures or an indwelling drainage catheter
- Have a history of severe infections within 4 weeks prior to the start of study treatment
- Hypertension (e.g., > 150/100 mmHg) that cannot be controlled by medications despite optimal medical therapy
- Other acute or chronic medical or psychiatric condition
- Have a history of immunodeficiency, with a positive human immunodeficiency virus(HIV) test at screening
- Known or suspected viral hepatitis with a positive test at screening
- Had an adverse reaction to a previous antitumor treatment that has not recovered to CTCAE Grade ≤ 1
- Have received chemotherapy within 4 weeks of the first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; small molecule inhibitors within 2 weeks before the first dose of IMP, or other investigational products within 4 weeks
- Current radiation-related toxicity or radiation therapy within 2 weeks before the first dose of IMP
- Administration of any of the following within 2 weeks before the first dose of IDE892 as a monotherapy: Strong inhibitors or inducers of cytochrome P450, Strong inhibitors of P-glycoprotein, Narrow therapeutic index and sensitive substrates of multidrug and toxin extrusion (MATE)1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and breast cancer resistance protein
- Administration of any of the following within 2 weeks before the first dose of IDE892: Strong inhibitors or inducers of CYP3A4/5, Strong inhibitors of P-gp and/or BCRP, Narrow therapeutic index and sensitive substrates of MATE1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and BCRP
- Use of proton pump inhibitors (PPIs) within 7 days prior to the first dose of IMP or planned use during the study
- Use of drugs with known risk for QT prolongation within 2 weeks prior to the first dose of IDE892
- Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor and/or Protein arginine N-methyltransferase (PRMT) inhibitor
- Major surgery within 4 weeks before study entry
- Prior irradiation to > 25% of the bone marrow
- Known or suspected hypersensitivity to IDE892
Disease-Specific Eligibility Criteria Eligibility Criteria for Participants with NSCLC (All Parts)
- Must have histologically confirmed diagnosis of advanced or metastatic NSCLC that has progressed after prior treatment with platinum chemotherapy and a PD-1/PD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting
- Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease.
- If considered standard of care and available, participants whose cancers have proven targetable oncogene alterations must have had disease progression on (unless contraindicated or participant developed intolerance) at least 1 prior line containing appropriate targeted therapy.
Eligibility Criteria for Participants with Urothelial Cancer (Bladder and Upper Urinary Tract), Mesothelioma (Pleural or Peritoneal), Pancreatic Adenocarcinoma or Biliary Tract Carcinomas (Intrahepatic and Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer) (Parts 1 and 3)
- Must have histologically confirmed diagnosis of advanced or metastatic UC, mesothelioma, gastroesophageal cancer or pancreatic and biliary tract tumors
- Must have progressed following at least 1 prior line of therapy
- Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Part 1: IDE892 Monotherapy Dose Escalation (MTAP-deleted advanced solid tumors)
Participants with advanced or metastatic solid tumors harboring MTAP deletion (including mesothelioma, gastroesophageal cancers, pancreatic and biliary tract tumors, non-small cell lung cancer, and urothelial cancer) will receive IDE892. Dose levels will be escalated sequentially using a Bayesian Optimal Interval (BOIN) design to evaluate safety, tolerability, and to determine the maximum tolerated dose and/or recommended dose for expansion. PK and pharmacodynamics (PD) and preliminary antitumor activity will also be assessed. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. |
|
Eksperymentalny: Part 2: IDE892 Monotherapy Dose Expansion (MTAP-Deleted NSCLC)
Participants with advanced or metastatic NSCLC with MTAP deletion will receive IDE892. One or more dose levels at or below the maximum tolerated dose from Part 1 will be further evaluated to determine the recommended Phase 2 dose and to assess antitumor activity. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. |
|
Eksperymentalny: Part 3: IDE892 + IDE397 Combination Dose Escalation (MTAP-Deleted Solid Tumors)
Participants with advanced or metastatic solid tumors harboring MTAP deletion (including mesothelioma, gastroesophageal cancers, pancreatic and biliary tract tumors, non-small cell lung cancer, and urothelial cancer) will receive IDE892 in combination with IDE397. Dose levels will be escalated using a modified toxicity probability interval (mTPI) design to evaluate safety, tolerability, and to determine the maximum tolerated dose and/or recommended dose for expansion. PK, PD, and preliminary antitumor activity will also be assessed. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors. |
|
Eksperymentalny: Part 4: IDE892 + IDE397 Combination Dose Expansion (MTAP-Deleted NSCLC)
Participants with advanced or metastatic NSCLC with MTAP deletion will receive IDE892 in combination with IDE397. One or more dose levels at or below the maximum tolerated dose from Part 3 will be further evaluated to determine the recommended Phase 2 dose and to assess antitumor activity. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)
Ramy czasowe: 21 days following the first dose of IDE892 (each cycle is 21 days)
|
Incidence of DLTs of IDE892 will be determined in Parts 1 and 3 |
21 days following the first dose of IDE892 (each cycle is 21 days)
|
|
Incidence of AEs and SAEs (Parts 1, 2, 3, and 4)
Ramy czasowe: From first dose until 28 days after last dose (each cycle is 21 days)
|
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) (graded based on Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) will be determined in Parts 1, 2, 3, and 4. |
From first dose until 28 days after last dose (each cycle is 21 days)
|
|
Objective response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts 2 and 4)
Ramy czasowe: Approximately 2 years
|
Objective response rate (ORR: best objective response of complete response [CR] + partial response [PR]) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the Investigator |
Approximately 2 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall response rate (ORR) and duration of response (DOR) per RECIST version 1.1 (Parts 1 and 3)
Ramy czasowe: Approximately 2 years
|
ORR and DOR per RECIST version 1.1 as assessed by the Investigator |
Approximately 2 years
|
|
Disease control rate (DCR) and duration of stable disease per RECIST version 1.1 (Parts 1, 2, 3, and 4)
Ramy czasowe: Approximately 2 years
|
Disease control rate (disease control rate [DCR]: CR + PR + stable disease [SD]) and duration of SD per RECIST version 1.1 as assessed by the Investigator |
Approximately 2 years
|
|
Maximum Observed Plasma Concentration (Cmax) (Parts 1, 2, 3, and 4)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Cmax is the highest observed plasma concentration of the study drug following administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time to Maximum Observed Concentration (Tmax)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Time to Maximum Observed Concentration (Tmax) after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
AUClast reflects total drug exposure from dosing until the last measurable concentration after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time of Last Quantifiable Concentration (Tlast)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Tlast is the time at which the final measurable drug concentration is observed after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
AUCinf represents total drug exposure extrapolated to infinite time after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Terminal Elimination Half-Life (t½)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
t½ is the time required for the plasma concentration of the drug to decrease by half during the terminal elimination phase after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Maximum Observed Plasma Concentration at Steady State (Cmax,ss)
Ramy czasowe: Cycle 1 Day 15 (each cycle is 21 days)
|
Cmax,ss is the maximum observed plasma concentration after achieving steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time to Maximum Concentration at Steady State (Tmax,ss)
Ramy czasowe: Cycle 1 Day 15 (each cycle is 21 days)
|
Tmax,ss is the time from dosing to Cmax at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Trough Plasma Concentration at Steady State (Ctrough)
Ramy czasowe: Cycle 1 Day 15 (each cycle is 21 days)
|
Ctrough is the concentration obtained immediately prior to the next scheduled dose at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau)
Ramy czasowe: Cycle 1 Day 15 (each cycle is 21 days)
|
AUCtau represents drug exposure over one full dosing interval at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Apparent Clearance (CL/F)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
CL/F is the apparent clearance of the drug after extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Apparent Volume of Distribution (Vz/F)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Vz/F is the apparent volume of distribution following extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Accumulation Ratio (Rac)
Ramy czasowe: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Rac is calculated as the ratio of AUC or Cmax at steady state compared with first dose, reflecting drug accumulation after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Edward Chan, MD, IDEAYA Biosciences
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby układu hormonalnego
- Procesy patologiczne
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Atrybuty choroby
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Nowotwory przewodu pokarmowego
- Nowotwory Układu Pokarmowego
- Choroby Układu Pokarmowego
- Choroby przewodu pokarmowego
- Choroby płuc
- Nowotwory gruczołów dokrewnych
- Nowotwory głowy i szyi
- Choroby trzustki
- Nowotwory gruczołowe i nabłonkowe
- Nowotwory Układu Oddechowego
- Nowotwory klatki piersiowej
- Procesy Nowotworowe
- Choroby przełyku
- Nowotwory płuc
- Gruczolak
- Nowotwory, mezotelium
- Nowotwory opłucnej
- Nowotwory urologiczne
- Rak
- Nowotwory, płaskonabłonkowy
- Choroby Pęcherza Moczowego
- Rak, płaskonabłonkowy
- Nowotwory przełyku
- Stany patologiczne, oznaki i objawy
- Rak płaskonabłonkowy przełyku
- Międzybłoniak złośliwy
- Nawrót
- Międzybłoniak
- Przerzuty nowotworu
- Nowotwory trzustki
- Nowotwory pęcherza moczowego
- Rak, komórka przejściowa
- Gruczolakoraka Przełyku
Inne numery identyfikacyjne badania
- IDE892-001
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .